parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in choroid plexus epithelial cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	3 Parkinson's papers of 1,040	0.82
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 12013

PRDM16 in dopamine neurons, braak-0.66 (p 0.051) → -0.37 (p 0.334)receipt 12021
PRDM16 in astrocytes, braak+0.09 (p 0.825) → -0.41 (p 0.273)receipt 12020

receipt 12021: PRDM16 in dopamine neurons, braak

power: full sample -0.40 (p 0.101, n 18), 95% CI -0.73 to +0.08. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.37 (p 0.127, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.56 (p 0.015, n 18). not the mix.
skeptic: leave-one-out range -0.52 to -0.32, sign flips 0; without severely affected donors -0.40 (p 0.101, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PRDM16 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12020: PRDM16 in astrocytes, braak

power: full sample -0.17 (p 0.509, n 18), 95% CI -0.59 to +0.33. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.15 (p 0.549, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.23 (p 0.369, n 18). could be the mix.
skeptic: leave-one-out range -0.30 to -0.06, sign flips 0; without severely affected donors -0.17 (p 0.509, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PRDM16 in astrocytes.

case closed: nothing better to follow up.

loading the receipts